A Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study

Summary

This is a multicenter, open-label extension study. Subjects who have received rhuMAb VEGF therapy in Study AVF2107g, AVF2119g, or AVF2192g and who completed the parent study are eligible for inclusion in this trial. Subjects who have received placebo in Study AVF2107g or AVF2192g are also eligible.

Timeline

Start

2002-10

Primary completion

—

Completion

2004-07

Drugs

Indications